Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emapalumab in macrophage activation syndrome associated with Still's disease or systemic lupus erythematosus
2021-001577-24Phase 2Active
- Sponsor
- Sobi
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of emapalumab in macrophage activation syndrome (MAS), adult-onset Still's disease (AOSD), systemic juvenile idiopathic arthritis (SJIA) and 1 more, sponsored by Sobi. Primary endpoint: Complete response at Week 8. Started Aug 2021; status: active.
02
Drugs
emapalumab
03
Conditions
macrophage activation syndrome (MAS)adult-onset Still's disease (AOSD)systemic juvenile idiopathic arthritis (SJIA)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2021-001577-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001577-24.